Connect with us

AI Research

AI fares better than doctors at predicting deadly complications after surgery

Published

on


A new artificial intelligence model found previously undetected signals in routine heart tests that strongly predict which patients will suffer potentially deadly complications after surgery. The model significantly outperformed risk scores currently relied upon by doctors.

The federally funded work by Johns Hopkins University researchers, which turns standard and inexpensive test results into a potentially lifesaving tool, could transform decision-making and risk calculation for both patients and surgeons.

“We demonstrate that a basic electrocardiogram contains important prognostic information not identifiable by the naked eye.”

Robert D. Stevens

Division of Informatics, Integration, and Innovation at Johns Hopkins Medicine

“We demonstrate that a basic electrocardiogram contains important prognostic information not identifiable by the naked eye,” said senior author Robert D. Stevens, chief of the Division of Informatics, Integration, and Innovation at Johns Hopkins Medicine. “We can only extract it with machine learning techniques.”

The findings are published today in the British Journal of Anaesthesia.

A substantial portion of people develop life-threatening complications after major surgery. The risk scores relied upon by doctors to identify who is at risk for complications are only accurate in about 60% of cases.

Hoping to create a more accurate way to predict these health risks, the Johns Hopkins team turned to the electrocardiogram, or ECG, a standard, pre-surgical heart test widely obtained before major surgery. It’s a fast, non-invasive way to evaluate cardiac activity through electric signals, and it can signal heart disease.

But ECG signals also pick up on other, more subtle physiological information, Stevens said, and the Hopkins team suspected they might find a treasure trove of rich, predictive data—if AI could help them see it.

“The ECG contains a lot of really interesting information not just about the heart but about the cardiovascular system,” Stevens said. “Inflammation, the endocrine system, metabolism, fluids, electrolytes—all of these factors shape the morphology of the ECG. If we could get a really big dataset of ECG results and analyze it with deep learning, we reasoned we could get valuable information not currently available to clinicians.”

Image caption: Stevens’ team used artificial intelligence to extract previously undetected signals in these routine heart tests that strongly predict which patients will suffer potentially deadly complications after surgery

Image credit: Will Kirk / Johns Hopkins University

The team analyzed preoperative ECG data from 37,000 patients who had surgery at Beth Israel Deaconess Medical Center in Boston.

The team trained two AI models to identify patients likely to have a heart attack, a stroke, or die within 30 days after their surgery. One model was trained on just ECG data. The other, which the team called a “fusion” model, combined the ECG information with more details from patient medical records such as age, gender, and existing medical conditions.

The ECG-only model predicted complications better than current risk scores, but the fusion model was even better, able to predict which patients would suffer post-surgical complications with 85% accuracy.

“Surprising that we can take this routine diagnostic, this 10 seconds worth of data, and predict really well if someone will die after surgery,” said lead author Carl Harris, a PhD student in biomedical engineering. “We have a really meaningful finding that can can improve the assessment of surgical risk.”

The team also developed a method to explain which ECG features might be associated with a heart attack or a stroke after an operation.

“You can imagine if you’re undergoing major surgery, instead of just having your ECG put in your records where no one will look at it, it’s run thru a model and you get a risk assessment and can talk with your doctor about the risks and benefits of surgery,” Stevens said. “It’s a transformative step forward in how we assess risk for patients.”

Next the team will further test the model on datasets from more patients. They would also like to test the model prospectively with patients about to undergo surgery.

The team would also like to determine what other information might be extracted from ECG results through AI.

Authors, all from the Johns Hopkins School of Medicine and the Whiting School of Engineering, include Anway Pimpalkar, Ataes Aggarwal, Jiyuan Yang, Xiaojian Chen, Samuel Schmidgall, Sampath Rapuri, Joseph L. Greenstein, and Casey O. Taylor.

The work was supported by National Science Foundation Graduate Research Fellowship DGE2139757.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

AI Research

Advarra launches AI- and data-backed study design solution to improve operational efficiency in clinical trials

Published

on


Advarra, the market leader in regulatory reviews and a leading provider of clinical research technology, today announced the launch of its Study Design solution, which uses AI- and data-driven insights to help life sciences companies design protocols for greater operational efficiency in the real world.

Study Design solution evaluates a protocol’s feasibility by comparing it to similar trials using Braid™, Advarra’s newly launched data and AI engine. Braid is powered by a uniquely rich set of digitized protocol-related documents and operational data from over 30,000 historical studies conducted by 3,500 sponsors. Drawing on Advarra’s institutional review board (IRB) and clinical trial systems, this dataset spans diverse trial types and therapeutic areas, provides granular detail on schedules of assessment, and tracks longitudinal study modifications, giving sponsors deeper insights than solutions based only on in-house or public datasets. 

“Too often, clinical trial protocols are developed without the benefit of robust comparative intelligence, leading to inefficient designs and operations,” said Laura Russell, senior vice president, head of data and AI product development at Advarra. “By drawing on the industry’s largest and richest operational dataset, Advarra’s Study Design solution delivers deeper insights into the feasibility of a protocol’s design. It helps sponsors better anticipate downstream operational challenges, make more informed decisions to simplify trial designs, and accelerate protocol development timelines.”

Advarra’s Study Design solution can be used to optimize a protocol prior to final submission or for retrospective analyses. The solution provides insights on design factors that drive operational feasibility, such as the impact of eligibility criteria, burdensomeness of the schedule of assessment on sites and participants, and reasons for amendments. Study teams receive custom benchmarking that allows for operational risk assessments through tailored data visualizations and consultations with Advarra’s data and study design experts. Technical teams can work directly within Advarra’s secure, self-service insights workspace to explore operational data for the purpose of powering internal analyses, models, and business intelligence tools.

“Early pilots have already demonstrated measurable impact,” added Russell. “In one engagement, benchmarking a sponsor’s protocol against comparable studies revealed twice as many exclusion criteria and 60 percent more site visits than industry benchmarks. With these insights, the sponsor saw a path to streamline future trial designs by removing unnecessary criteria, clustering procedures, and adopting hybrid visit models, ultimately reducing site burden and making participation easier for patients.”

Study Design solution is the first in a series of offerings by Advarra that will be powered by Braid. Future applications will extend insights beyond protocol design to improve study startup, enhance collaboration, and better support sites.

To learn more about Study Design solution or to request a consultation, visit advarra.com/study-design.

About Advarra
Advarra breaks the silos that impede clinical research, aligning patients, sites, sponsors, and CROs in a connected ecosystem to accelerate trials. Advarra is number one in research review services, a leader in site and sponsor technology, and is trusted by the top 50 global biopharma sponsors, top 20 CROs, and 50,000 site investigators worldwide. Advarra solutions enable collaboration, transparency, and speed to optimize trial operations, ensure patient safety and engagement, and reimagine clinical research while improving compliance. For more information, visit advarra.com.

 



Source link

Continue Reading

AI Research

Best Artificial Intelligence (AI) Stock to Buy Now: Nvidia or Palantir?

Published

on


Palantir has outperformed Nvidia so far this year, but investors shouldn’t ignore the chipmaker’s valuation.

Artificial intelligence (AI) investing is a remarkably broad field, as there are numerous ways to profit from this trend. Two of the most popular are Nvidia (NVDA -1.55%) and Palantir (PLTR -0.58%), which represent two different sides of AI investing.

Nvidia is on the hardware side, while Palantir produces AI software. These are two lucrative fields to invest in, but is there a clear-cut winner? Let’s find out.

Image source: Getty Images.

Palantir’s business model is more sustainable

Nvidia manufactures graphics processing units (GPUs), which have become the preferred computing hardware for processing AI workloads. While Nvidia has made a ton of money selling GPUs, it’s not done yet. Nvidia expects the big four AI hyperscalers to spend around $600 billion in data center capital expenditures this year, but projects that global data center capital expenditures will increase to $3 trillion to $4 trillion by 2030. That’s a major spending boom, and Nvidia will reap a substantial amount of money from that rise.

However, Nvidia isn’t completely safe. Its GPUs could fall out of style with AI hyperscalers as they develop in-house AI processing chips that could steal some of Nvidia’s market share. Furthermore, if demand for computing equipment diminishes, Nvidia’s revenue streams could fall. That’s why a subscription model like Palantir is a better business over the long term.

Palantir develops AI software that can be described as “data in, insights out.” By using AI to process a ton of information rapidly, Palantir can provide real-time insights for what those with decision-making authority should do. Furthermore, it also gives developers the power to deploy AI agents, which can act autonomously within a business.

Palantir sells its software to commercial clients and government entities, and has gathered a sizable customer base, although that figure is rapidly expanding. As the AI boom continues, these customers will likely stick with Palantir because it’s incredibly difficult to move away from the software once it has been deployed. This means that after the AI spending boom is complete, Palantir will still be able to generate continuous revenue from its software subscriptions.

This gives Palantir a business advantage.

Nvidia is growing faster

Although Palantir’s revenue growth is accelerating, it’s still slower than Nvidia’s.

NVDA Revenue (Quarterly YoY Growth) Chart

NVDA Revenue (Quarterly YoY Growth) data by YCharts

This may invert sometime in the near future, but for now, Nvidia has the growth edge.

One item that could reaccelerate Nvidia’s growth is the return of its business in China. Nvidia is currently working on obtaining its export license for H20 chips. Once that is returned, the company could see a massive demand from another country that requires significant AI computing power. Even without a massive chunk of sales, Nvidia is still growing faster than Palantir, giving it the advantage here.

Nvidia is far cheaper than Palantir

With both companies growing at a similar rate, it would be logical to expect that they should trade within a similar valuation range. However, that’s not the case. Whether you analyze the stocks from a forward price-to-earnings (P/E) or price-to-sales (P/S) basis, Palantir’s stock is unbelievably expensive.

NVDA PE Ratio (Forward) Chart

NVDA PE Ratio (Forward) data by YCharts

From a P/S basis, Palantir is about 5 times more expensive than Nvidia. From a forward P/E basis, it’s about 6.5 times more expensive.

With these two growing at the same rate, this massive premium for Palantir’s stock doesn’t make a ton of sense. It will take years, or even a decade, at Palantir’s growth rate to bring its valuation down to a reasonable level; yet, Nvidia is already trading at that price point.

I think this gives Nvidia an unassailable advantage for investors, and I think it’s the far better buy right now, primarily due to valuation, as Palantir’s price has gotten out of control.

Keithen Drury has positions in Nvidia. The Motley Fool has positions in and recommends Nvidia and Palantir Technologies. The Motley Fool has a disclosure policy.



Source link

Continue Reading

AI Research

Is AI the 4GL we’ve been waiting for? – InfoWorld

Published

on



Is AI the 4GL we’ve been waiting for?  InfoWorld



Source link

Continue Reading

Trending